The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think
about cancer treatment. Even so, for most types of cancer, only a minority of patients currently …

Purpose: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to
sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published …

Background Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy
than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess …

BACKGROUND Phase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT)
was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) …

In recent years, the application of advanced analytics, especially artificial intelligence (AI), to
digital H&E images, and other histological image types, has begun to radically change how …

Diverse extracellular matrix patterns are observed in both normal and pathological tissue.
However, most current tools for quantitative analysis focus on a single aspect of matrix …

Cancer patients with low or absent pre-existing anti-tumour immunity (“cold” tumours)
respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these …

Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell‐autonomous
mechanisms of cell death. Here, tumour cell death occurs when a threshold …

Calcium ions play key roles as structural components in biomineralization and as a second
messenger in signaling pathways. We have introduced a de novo designed calcium-binding …

Crigler‐Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a
marked decrease in uridine‐diphosphate‐glucuronosyltransferase (UGT1A1) enzyme activity. …